Home » AVANT: GLAXO PAID ROYALTIES AT LOW RATE
AVANT: GLAXO PAID ROYALTIES AT LOW RATE
Vaccine developer Avant Immunotherapeutics
Inc. said that GlaxoSmithKline PLC has paid royalties on its sales of Rotarix
rotavirus vaccine in Australia and certain European countries at the lower of
two rates established under the companies' 1997 license agreement.
Boston
Globe
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct